Michael P. Cecil, M.D.

Michael P. Cecil, M.D.


Recent articles

Berkshire Hathaway's Next CEO?

The man who might replace the king writes about his own business principles and strategies.

Stents on Trial

New study results could affect stent sales -- at least in the short term.

Will a 10-Bagger Go Higher?

One study could boost the stock of a company with a special machine for heart patients.

An Opening for Plavix

New data suggesting problems with drug-eluting stents may translate into more sales of the blood thinner and fewer sales of the stents.

Bad News Is Good News for Pfizer

Celebrex is still shown to increase the risk of heart problems, but that might not be bad news for Pfizer shareholders.

A Drug-Price Avalanche?

Wal-mart's $4 generic-drug program could be the start of big changes in the $250 billion prescription-drug market.